Biblio

Duron DI, Tanguturi P, Campbell CS, Chou K, Bejarano P, Gabriel KA, Bowden JL, Mishra S, Brackett C, Barlow D et al..  2024.  Inhibiting spinal cord-specific hsp90 isoforms reveals a novel strategy to improve the therapeutic index of opioid treatment.. Sci Rep. 14(1):14715.

Martin LF, Cheng K, Washington SM, Denton M, Goel V, Khandekar M, Largent-Milnes TM, Patwardhan A, Ibrahim MM.  2023.  Green Light Exposure Elicits Anti-inflammation, Endogenous Opioid Release and Dampens Synaptic Potentiation to Relieve Post-surgical Pain.. J Pain. 24(3):509-529.

Gabriel KA, Streicher JM.  2023.  HSP90 inhibition in the mouse spinal cord enhances opioid signaling by suppressing an AMPK-mediated negative feedback loop.. Sci Signal. 16(780):eade2438.

Varga BR, Streicher JM, Majumdar S.  2023.  Strategies towards safer opioid analgesics-A review of old and upcoming targets.. Br J Pharmacol. 180(7):975-993.

Keresztes A, Olson K, Nguyen P, Lopez-Pier MA, Hecksel R, Barker NK, Liu Z, Hruby V, Konhilas J, Langlais PR et al..  2022.  Antagonism of the mu-delta opioid receptor heterodimer enhances opioid antinociception by activating Src and calcium/calmodulin-dependent protein kinase II signaling.. Pain. 163(1):146-158.

Tanguturi P, Pathak V, Zhang S, Moukha-Chafiq O, Augelli-Szafran CE, Streicher JM.  2021.  Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists.. Molecules. 26(21)

Duron DI, Hanak F, Streicher JM.  2020.  Daily intermittent fasting in mice enhances morphine-induced antinociception while mitigating reward, tolerance, and constipation.. Pain. 161(10):2353-2363.

Stine C, Coleman DL, Flohrschutz AT, Thompson AL, Mishra S, Blagg BS, Largent-Milnes TM, Lei W, Streicher JM.  2020.  Heat shock protein 90 inhibitors block the antinociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models.. Pain. 161(8):1798-1807.

Lei W, Vekariya RH, Ananthan S, Streicher JM.  2020.  A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.. J Pain. 21(1-2):146-160.

Olson KM, Duron DI, Womer D, Fell R, Streicher JM.  2019.  Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids.. PLoS One. 14(6):e0217371.

Streicher JM, Bilsky EJ.  2018.  Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.. J Pharm Pract. 31(6):658-669.

Lei W, Mullen N, McCarthy S, Brann C, Richard P, Cormier J, Edwards K, Bilsky EJ, Streicher JM.  2017.  Heat-shock protein 90 (Hsp90) promotes opioid-induced anti-nociception by an ERK mitogen-activated protein kinase (MAPK) mechanism in mouse brain.. J Biol Chem. 292(25):10414-10428.

Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE.  2016.  17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.. ACS Chem Neurosci. 7(3):297-304.

Deekonda S, Wugalter L, Kulkarni V, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porreca F et al..  2015.  Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.. Bioorg Med Chem. 23(18):6185-94.

Largent-Milnes TM, Brookshire SW, Skinner DP, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S et al..  2013.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.. J Pharmacol Exp Ther. 347(1):7-19.

Podolsky AT, Sandweiss A, Hu J, Bilsky EJ, Cain JP, Kumirov VK, Lee YSun, Hruby VJ, Vardanyan RS, Vanderah TW.  2013.  Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.. Life Sci. 93(25-26):1010-6.

Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.  2012.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.. J Neuroimmunol. 244(1-2):23-31.

Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.  2012.  Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.. Eur J Pharmacol. 684(1-3):64-70.

Lochhead JJ, McCaffrey G, Sanchez-Covarrubias L, Finch JD, DeMarco KM, Quigley CE, Davis TP, Ronaldson PT.  2012.  Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain.. Am J Physiol Heart Circ Physiol. 302(3):H582-93.

Lee YSun, Kulkarani V, Cowell SM, Ma S-W, Davis P, Hanlon KE, Vanderah TW, Lai J, Porreca F, Vardanyan R et al..  2011.  Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.

Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, Guo W, Lee Y-S, Ossipov MH, Hruby VJ et al..  2011.  Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.. Brain Res. 1395:1-11.

Vardanyan R, Kumirov VK, Nichol GS, Davis P, Liktor-Busa E, Rankin D, Varga E, Vanderah T, Porreca F, Lai J et al..  2011.  Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.. Bioorg Med Chem. 19(20):6135-42.

Tarselli MA, Raehal KM, Brasher AK, Streicher JM, Groer CE, Cameron MD, Bohn LM, Micalizio GC.  2011.  Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain.. Nat Chem. 3(6):449-53.

Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, Vanderah TW.  2010.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.. Br J Pharmacol. 161(5):986-1001.

Tumati S, Milnes TLargent, Yamamura HI, Vanderah TW, Roeske WR, Varga EV.  2008.  Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.. Eur J Pharmacol. 601(1-3):207-8.